Plain-English translation of NCT06748937 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new antibiotic called alpibectir combined with other tuberculosis medications to see if it works well and is safe for patients. Researchers want to find the right doses of the medication and understand how well it kills the TB bacteria in your body. The study will last 14 days, during which you'll stay in the hospital so doctors can monitor you closely.
Current TB treatments don't always work for every patient, especially when the TB bacteria become resistant to standard drugs. This study is exploring whether this new medication could offer an alternative treatment option that is easier to take and works well, particularly for patients in parts of the world with limited access to healthcare.
You likely qualify if…
You likely don't qualify if…
You would be admitted to the hospital for 15 days. During this time, you would take the study medications by mouth once daily, along with other standard TB drugs. Doctors would monitor your health closely through blood tests, heart rhythm checks, and sputum samples to measure how well the medication is killing the TB bacteria. You would remain in the hospital throughout the study period to ensure your safety and allow for continuous medical supervision.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Africa